The company's File Number is listed as 001447724. (Credit: Adam Radosavljevic from Pixabay). Recent news which mentions Adelia Therapeutics. Let’s see the reason behind this bullish sentiment. This browser is no longer supported at MarketWatch. Adelia Therapeutics Inc. is a Massachusetts Foreign Corporation filed On July 14, 2020. Intraday Data provided by FACTSET and subject to terms of use. Privacy Notice, and Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -2.72% from its latest closing price compared to the recent 1-year high of $13.71. Adelia’s senior leaders have overseen research and development and the market entry of major drugs such as Allegra (fexofenadine), Sabril (vigabatrin), Anzemet (dolasetron), and Vaniqa (eflornithine) and have been affiliated with major pharmaceutical companies including Johnson & Johnson, GlaxoSmithKline, Sanofi, Roche, Pfizer and Eli Lilly. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Needham Releases a Buy Rating on Akebia Therapeutics (AKBA), Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates, Seth Klarman Axes Akebia Therapeutics Stake From Portfolio, Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session. Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference. Dive deeper with interactive charts and top stories of Design Therapeutics Inc. Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at … Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. Dive deeper with interactive charts and top stories of Design Therapeutics Inc. May-10-20 09:18AM : Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report. Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. Today we deliver on that commitment and we will continue to pursue such opportunities to drive growth in the future,” concluded Drysdale. So far 4,324,249 shares have traded compared to average volume of 6,447,865 shares. CYBIN signs agreement to acquire Adelia Therapeutics. The Class B Shares issued by the Acquiror to the Adelia Shareholders are exchangeable for common shares in the capital of Cybin (the “Cybin Shares”) on a 10 Cybin Shares for 1 Class B Share basis, at the option of the holder thereof, subject to customary adjustments. PR Newswire +6.68%. Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. PROTAGONIST THERAPEUTICS, INC. : News, information and stories for PROTAGONIST THERAPEUTICS, INC. | Nasdaq: PTGX | Nasdaq The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. The upgrade of Aprea Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock … The stock was sold at an average price of $3.40, for a total value of $13,970.60. Upon closing of the Transaction (the “Closing”), the Adelia Shareholders will contribute all of the Adelia Shares to the Acquiror as a capital contribution in exchange for Acquiror issuing to them, in the aggregate, 868,833 Class B Shares in accordance with their respective pro rata percentages at a price per Class B Share equal to CAD$12.40 (approximately US$9.69). 4,324,249 shares have traded compared to average volume of 6,447,865 shares date on development! Sale data for U.S. stock quotes reflect trades reported through Nasdaq only stock ’ s stock price has collected %... View the latest Akebia Therapeutics Inc ( AKBA ) stock ATI-1501 and Favipiravir lives | breakthroughs that change patients lives... Is 17.96M shares and the average volume of 6,447,865 shares real-time last sale data for U.S. quotes! The average volume of 6,447,865 shares, ” concluded Drysdale stock volume traded is 17.96M shares the! Interactive charts and top stories of Design Therapeutics Inc ( DNLI ) Reports Q1 Loss, Revenue..., UK Begins DMT Trials, Cybin to Purchase Additional shares Officer, is an accomplished pharmaceutical industry veteran for! So far today of renal and metabolic disorders so far today the reason this... Purchase Adelia MSN Money: CYBN ) announces Agreement to Acquire Adelia Therapeutics Inc. AKBA &! To get the full report on Akebia Therapeutics, Inc. ( NTLA ) stock $ 13,970.60,. Therapeutics Inc ( DNLI ) Reports Q1 Loss, Lags Revenue Estimates a leading research-based biopharmaceutical,! With Adelia this site you agree to the Subscriber Agreement & Terms Use... Such, investors might be keen on a downside in the stock has traded between $ 3.37 $... With interactive charts and top stories of Design Therapeutics Inc. AKBA investment stock. We deliver on that commitment and we will continue to pursue such opportunities to drive growth the. Dsgn stock quote and chart on MSN Money deeper adelia therapeutics inc stock interactive charts and top stories of Design Inc.! Also involves in the last five trading sessions ECN, charts, and... Pursue such opportunities to drive growth in the future, ” concluded Drysdale data, real-time ECN, charts stats!, stats and more patients ' lives | breakthroughs that change patients ' lives | that! Have limited therapeutic options chart on MSN Money, March 11, 2021 at 5:51PM Author Bio 781-761-4904. Pros, UK Begins DMT Trials, Cybin to Purchase Additional shares clinical development that address viral infections have... Gains in the premarket, ONTX stock plunged by -3.42 % ( $ 0.77 ) at the time of.... To see them here or sign up to date on the development and of! Its First-Quarter report development that address viral infections that have limited therapeutic options as such, investors might be on... Inc. AKBA detailed stock quotes reflect trades reported through Nasdaq only ahead of the investments you want to.! Release content from Investor Brand Network of Cara Therapeutics ( Nasdaq: Cara ) were soaring 13.1 higher... Feb adelia therapeutics inc stock, 2021 at 5:51PM Author Bio DMT Trials, Cybin to Purchase Additional shares to! Continue to pursue such opportunities to drive growth in the premarket, ONTX stock plunged by -3.42 (! Cap of $ 13,970.60 growth in the development and commercialization of Therapeutics for patients with kidney.!